Aclaris Prices $50M Offering at $3.50, a 7.7% Discount to Last Sale, Alongside Positive ATI-052 Data
ACRS sits 77% above its 52-week low of $2.1 on elevated volume (2.8× avg).
Summary
Aclaris priced a $50.0 million underwritten offering at $3.50 per share (a discount to the $3.79 last sale) plus pre-funded warrants on 6.5 million shares, netting about $46.7 million the same day it reported positive ATI-052 Phase 1b data.
Key Events · Financing and Capital Events · ACRS
-
Priced $50M Underwritten Offering
The deal comprises 7,785,714 common shares at $3.50 plus pre-funded warrants on 6,500,000 shares at $3.49999 each, for $49,999,934 gross.
-
Net Proceeds and Fees
Underwriting discounts of $0.21 per share ($3,000,000 total) and about $300,000 of estimated expenses leave roughly $46.7 million net to Aclaris.
-
Priced Below Last Sale
Against a last reported sale of $3.79 on October 26, 2026, the $3.50 offering price means new buyers face $2.06 per share of immediate net tangible book value dilution.
-
Cash Position and Use of Proceeds
Preliminary unaudited cash, cash equivalents and marketable securities stood at about $204.6 million at September 30, 2026; proceeds go to pipeline R&D, including a Phase 2b ATI-052 trial in EoE targeted for early 2027, and to working capital.
Analysis · ACRS · Life Sciences
The timing is what matters here: Aclaris priced this deal the same morning it reported positive Phase 1b results for ATI-052 in atopic dermatitis and asthma, capitalizing on the data-driven move rather than raising from a position of weakness. Gross proceeds came to $50.0 million ($46.7 million net) from 7,785,714 shares at $3.50 and, for buyers who preferred it, pre-funded warrants on 6,500,000 shares at $3.49999 each. Because the $3.50 price sits below the $3.79 last reported sale on October 26, the deal cleared at a discount to where the stock was trading, and new buyers absorb $2.06 per share of immediate book-value dilution. With roughly $204.6 million of cash at September 30 before this raise, the proceeds fund the planned Phase 2b trial of ATI-052 in eosinophilic esophagitis targeted for early 2027 and extend the runway well beyond that. Near-term supply is limited by the 60-day lock-up and the bar on ATM sales for 30 days, but the offering itself adds roughly 14.3 million shares-equivalent to a base of 139.8 million outstanding as of June 30.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRS was trading at $3.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557.9M. The 52-week trading range was $2.10 to $6.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.